Trials / Completed
CompletedNCT05146999
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | QM1114-DP | QM1114-DP |
| BIOLOGICAL | Placebo | Placebo |
Timeline
- Start date
- 2022-05-09
- Primary completion
- 2022-10-28
- Completion
- 2023-09-01
- First posted
- 2021-12-07
- Last updated
- 2024-10-21
- Results posted
- 2024-10-21
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05146999. Inclusion in this directory is not an endorsement.